HKD 6.95
(0.14%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -539.65 Million CNY | -0.26% |
2022 | -538.28 Million CNY | -71.44% |
2021 | -313.98 Million CNY | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -109.87 Million CNY | 0.0% |
2024 Q1 | -109.87 Million CNY | 32.34% |
2023 Q4 | -162.4 Million CNY | 0.0% |
2023 Q3 | -162.4 Million CNY | -51.18% |
2023 FY | -539.65 Million CNY | -0.26% |
2023 Q2 | -107.42 Million CNY | 0.0% |
2023 Q1 | -107.42 Million CNY | -19.98% |
2022 FY | -538.28 Million CNY | -71.44% |
2022 Q4 | -89.53 Million CNY | 0.0% |
2022 Q3 | -89.53 Million CNY | 0.0% |
2021 FY | -313.98 Million CNY | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Uni-Bio Science Group Limited | 67.76 Million HKD | 896.326% |
CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 160.098% |